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Quantifying rotavirus shedding among vaccinated individuals 
will aid understanding of vaccine indirect effects. Serial stool 
samples were collected from 196 children who presented with 
rotavirus gastroenteritis to health facilities in Blantyre, Malawi, 
and were tested for rotavirus using a VP6 semi-quantitative, 
real-time polymerase chain reaction. The median duration of 
fecal shedding was 28 days (95% CI, 19–28). The median copy 
numbers for peak shedding were 1.99 × 107 (interquartile range, 
3.39 × 106 to 6.37 × 107). The fecal viral load was positively as-
sociated with disease severity and negatively associated with 
serum anti-rotavirus immunoglobin A. High and persistent ro-
tavirus shedding among vaccinated children with breakthrough 
disease may contribute to ongoing transmission in this setting.
Keywords. rotavirus; transmission; vaccine effectiveness; 
shedding.
Rotavirus vaccine has been introduced in over 90 countries 
worldwide, including 45 low-income or GAVI Alliance-eligible 
countries [1]. However, rotavirus vaccine effectiveness is re-
duced in low-income countries (LIC) [2], and in several coun-
tries rotavirus remains the commonest cause of hospitalized 
gastroenteritis in children <5 years, despite high vaccine cov-
erage [3]. Vaccine effectiveness is higher against severe rotavirus 
disease than milder disease [4], but the impact of vaccination 
on fecal shedding (and therefore infectiousness) amongst vac-
cinated individuals with breakthrough rotavirus disease is un-
known. Differences in the intensity of fecal-oral transmission of 
rotavirus between settings (force of infection) may contribute 
to the observed variation in vaccine performance, but few data 
exist on individual-level fecal shedding, which is the primary 
mechanism of rotavirus transmission.
The dynamics of fecal shedding of rotavirus in unvaccinated 
populations has been examined in children with both asymp-
tomatic rotavirus infection and with clinical rotavirus disease 
using electron microscopy, enzyme-immune assay, and pol-
ymerase chain reaction (PCR) [5]. Fecal shedding has been 
shown to extend beyond symptom resolution, persisting for a 
median of 10 days after symptom onset in Australia and 24 days 
in India when using PCR-based assays [6, 7]. A positive rela-
tionship between fecal viral load and disease severity was dem-
onstrated among Indian children [5].
There is a lack of shedding data from vaccinated infants 
in any setting, including infants from sub-Saharan Africa, 
in whom differences in intestinal integrity, nutritional state, 
comorbidities, and immune responses may lead to variations 
in shedding, with concomitant impacts on transmission. We 
aimed to describe patterns of wild-type rotavirus shedding over 
time and identify the factors associated with fecal viral load 
in children age-eligible for vaccination with symptomatic ro-
tavirus disease in Malawi, an LIC in southern Africa. The live 
oral monovalent rotavirus vaccine was introduced into Malawi’s 
national immunization program on 29 October 2012, with 
doses at 6 and 10 weeks of age.
METHODS
Children age-eligible for vaccination (born on or after 12 
September 2012 and >6 weeks old) presenting with acute gastro-
enteritis to Queen Elizabeth Central Hospital and to 3 govern-
ment health centers in Blantyre, Malawi, between 16 February 
2015 and 11 November 2016 were tested for rotavirus using 
immunochromatographic tests on a fecal sample. Following in-
formed consent, rotavirus-positive children had demographic 
data and 2 mls of serum collected at recruitment to measure 
anti-rotavirus immunoglobin (Ig) A titres; a second bulk stool 
sample was obtained 48 hours after presentation (primary co-
hort). A subset of children had more intensive stool sampling 
carried out for 28  days (intensive cohort); samples were col-
lected daily from the time of presentation for the first 7 days 
after symptom onset, twice weekly from 7 until 14  days, and 
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Data Collection
Disease severity was defined using the 20-point Vesikari score 
(<7 indicates mild, 7–10 indicates moderate, and ≥11 indicates 
severe disease). Severe acute malnutrition was defined by ei-
ther a weight-for-height Z-score (WHZ) less than -3 standard 
deviations, a mid–upper arm circumference <115 mm, or nu-
tritional edema [8]. Weights were adjusted for percentage de-
hydration prior to calculating anthropometric indices. Data 
on human immunodeficiency virus (HIV) status and vaccine 
status were collected from government-issued health pass-
ports. HIV testing was performed by the government health 
system. An HIV infection was defined as a positive HIV 
rapid test (≥12  months of age) or positive HIV DNA PCR 
(<12 months). Children of HIV-positive mothers were defined 
as HIV-exposed.
Laboratory Procedures
Stool samples were tested for wild-type rotavirus using a real-
time semi-quantitative reverse transcription PCR [5]. An ad-
ditional real-time semi-quantitative reverse transcription PCR 
targeting a distinct rotavirus gene (NSP3) was run on each 
sample with a cycle threshold value in the range of 35–40 as 
a confirmatory assay [9]. Due to the lack of reproducibility in 
samples with very low viral loads, samples were defined as ro-
tavirus positive if they had ≥100 viral copy numbers and were 
positive on an NSP3 assay.
Serum anti-rotavirus IgA titres were measured using a semi-
quantitative sandwich enzyme-linked immunosorbent assay 
[10]. Results were calculated on a minimum of 2 values per 
sample with a coefficient of variation <20% and were expressed 
as geometric mean titres (IU/ml).
Statistical Analysis
The viral load data did not follow a normal distribution, so were log-
transformed for analysis. Risk factors for fecal viral shedding den-
sity were investigated using multivariable linear regression, where 
the outcome variable was the peak log-viral load (the largest value 
obtained from the 2 samples) in children from the primary cohort. 
Variables achieving a Wald test P value of ≤.1 on a univariate anal-
ysis were selected for evaluation in the multivariable model. Nested 
models were compared using F tests. Variables which improved the 
model fit (P ≤ .05) were retained in the final model.
Data from the intensive cohort were used to evaluate changes 
in viral load over time using linear mixed models with a random 
intercept to account for within-child clustering; for this anal-
ysis, all data were included, regardless of viral load. Polynomial 
terms (quadratic and cubic) were included to account for the 
non-linear relationship between fecal viral load and time.
A time-to-event analysis was used to estimate the duration of 
viral shedding in children from the intensive cohort. The event 
of interest was defined as the cessation of shedding and the start 
time for analysis was the onset of symptoms. Cessation of shed-
ding was defined as the last time point from which rotavirus 
could be detected until censoring. Thus, an individual with no 
detectable rotavirus at a given analytical time point but who 
was shedding rotavirus in subsequent samples was classified as 
having ongoing shedding at the time of analysis. The follow-up 
was limited to 28 days.
RESULTS
We recruited 196 index children, from whom 374 fecal samples 
were collected (Supplementary Table S1). Of these children, 21 
were also recruited into the intensive cohort and had a fur-
ther 136 samples collected. The median age of all children 
was 11.5 months (interquartile range, 8.8–15.2). A total of 25 
(13%) children were exposed to HIV. Of children with docu-
mented HIV test results, 2/58 (3.5%) were infected with HIV. 
The majority of children had severe rotavirus gastroenteritis 
(168/193, 86.5%). The median number of anti-rotavirus IgA 
titres at presentation was 4 IU/ml (range, 0–831), and 27% 
(45/164) children met the traditional threshold for seroconver-
sion (>20 IU/ml) [10]. The 2-dose rotavirus vaccine coverage 
was 194/196 (99.0%).
Predictors of Viral Load: Primary Cohort
The median copy numbers for peak shedding were 1.99 × 107 
(interquartile range, 3.39 × 106 to 6.37 × 107). The 2 unvac-
cinated children had peak viral loads comparable to the vac-
cinated children (median peak shedding, 9.64  ×  106). In a 
multivariable analysis, a positive association between peak 
shedding density and Vesikari score and a negative associa-
tion between peak shedding density and IgA titres were iden-
tified (Table 1). The reference group used for Vesikari (mild 
disease) contains only 3 observations; however, the relation-
ship between Vesikari score and viral load persisted when 
Vesikari was coded as a continuous variable or as 3 approx-
imately equal groups (Supplementary Table S2). There was 
also weak evidence of a negative association between the viral 
load and WHZ.
Change in Viral Load Over Time and Duration of Viral Shedding: 
Intensive Cohort
The viral loads ranged from 21 to 1.91 × 109 copies. They de-
clined significantly with the time from symptom onset (the 
regression coefficient for the relationship between log copy 
numbers and time in days since symptom onset, -1.68; 95% CI, 
-2.51 to -.85; Figure 1A; Supplementary Table S3). The viral 
loads were significantly higher when children were sympto-
matic (regression coefficient, 6.94; 95% CI, 5.15–8.73). This 
effect was reduced when adjusted for the time from symptom 
onset (regression coefficient, 1.87; 95% CI, .25–3.49). The pro-
portion of children shedding rotavirus declined over time, 
from 100% at the first visit to 20% at the end of follow-up 
(Figure 1B). The median duration of shedding, based on a 
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DISCUSSION
In a cohort of vaccinated Malawian children with rotavirus 
gastroenteritis, children shed rotavirus in high densities at 
the time of initial symptom onset and continued to shed 
rotavirus for an extended period of time after symptom 
resolution. The fecal viral shedding density was positively 
Table 1. Predictors of Peak Viral Shedding Density
Covariate n
Univariate Association With Peak Viral 
Load (95% CI) P Value
Multivariate Association With Peak Viral 
Load (95% CI) P Value
Sex, male 195 -.58 (-1.35 to .20) .143 … …
Age in months 195 -.04 (-.10 to .02) .244 … …
HIV exposed 195 .12 (-1.04 to 1.28) .837 … …
HIV infected 58 .58 (-3.55 to 4.71) .779 … …
Premature 195 .33 (-1.76 to 2.42 ) .755 … …
Birth weight, kgs 195 .29 (-.34 to .93) .365 … …
Ever breast fed 195 -1.18 (-6.61 to 4.26) .670 … …
SAM 193 .16 (-1.05 to 1.37) .793 … …
WHZ 194 -.39 (-.63 to -.15) .001 -.24 (-.49 to .01) .060
WAZ 194 .09 (-.24 to .43) .565 … …
HAZ 190 .28(.12–.43) .001 … …
MUAC, cm 194 -.26 (-.56 to .04) .089 … …
Diarrhea episodes/day 195  … … … …
 1-3 … REF … … …
 4-5 … .61 (-.66 to .88) .343 … …
 ≥6 … .70 (-.57 to 1.97) .277 … …
Diarrhea duration, days 195  … … … …
 1-4 … REF … … …
 5 … 1.59 (-.01 to 3.20) .052 … …
 ≥6 … -.45 (-2.12 to 1.22) .596 … …
Vomiting 195 … … … …
 Yes … 1.81 (.33–3.29) .017 … …
Vomiting frequency/day 181 … … … …
 <5 … REF … … …
 ≥5 … .07 (-.75 to .89) .868 … …
Vomiting duration, days 181 … … … …
 1 … REF … … …
 2 … .65 (-.61 to 1.91) .310 … …
 ≥6 … 1.33 (.15–2.52) .028 … …
Dehydration 195 … … … …
 None … REF … … …
 Some … .66 (-.52 to 1.84) .271 … …
 Severe … 1.31 (-.03 to 2.65) .055 … …
IV fluids 195 … … … …
 Yes … .57 (-.28 to 1.40) .195 … …
Oral fluids 195 … … … …
 Yes … .25 (-1.43 to 1.94) . 767  … …
Admission 195 … … … …
 Yes … .96 (.19–1.73) .015 … …
Outcome 195 … … … …
 Home … REF … … …
 Died … -2.05 (-5.89 to 1.80) .294 … …
Vesikari score 192 … … … …
 Mild 3 REF … REF …
 Moderate 23 8.27 (5.18–11.35) .000 7.92 (4.96–10.90) .000
 Severe 167 8.46 (5.53–11.38) .000 8.04 (5.23–10.84) .000
IgA titre at presentation 163 -.27 (-.48 to -.07) .010 -.21 (-.40 to -.02) .032
Time from symptom onset 193 -.09(-.33 to .15) .475 … …
Abbreviations: HAZ, height for age Z score; HIV, human immunodeficiency virus; Ig, immunoglobin; IV, intravenous; MUAC, mid–upper arm circumference; REF, indicates reference category;
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associated with  disease severity and negatively associated 
with anti-rotavirus IgA titres.
The pattern of rotavirus shedding observed among symp-
tomatic rotavirus cases is similar to that reported among un-
vaccinated children from India [7]. In both Malawi and India, 
high viral titres on presentation rapidly declined over the first 
10  days after symptom onset and then plateaued, with a me-
dian duration of shedding of approximately 4 weeks (28 days in 
Malawi, 24 days in India). This is substantially longer than the 
median duration of shedding reported from Australia (10 days) 
[6]. While this could reflect differences in the sensitivities of the 
assays used, the immune responses to both natural rotavirus 
infection and rotavirus vaccine are reduced in LICs, compared 
to higher-income settings [11]. The extended duration of shed-
ding could, therefore, result from a delayed clearance of the 
replicating virus as a result of sub-optimal mucosal immunity, 
or very high rates of reinfection. A high frequency of asympto-
matic rotavirus shedding has been described in young children 
from Malawi [12], and this may be partly explained by the pro-
longed fecal shedding of rotavirus following a symptomatic 
infection. Due to logistical restraints, the duration of follow-up 
in this study was limited, and the reported duration of shedding 
represents a minimum estimate. This is especially relevant con-
sidering our definition of cessation of shedding; it is possible 
that some of the children near the end of follow-up were mis-
classified as having stopped shedding.
Children who develop severe rotavirus disease despite 
being vaccinated shed large quantities of the virus. This may 
contribute to the ongoing community transmission of ro-
tavirus and could partly explain the persisting high burden 
of disease in LICs, where indirect (herd) protection appears 
limited despite high vaccine coverage [4]. However, it is no-
table that recruitment into this study was biased towards 
those children with severe disease presenting to health-care 
facilities. In our cohort, disease severity was significantly 
associated with viral load; children with moderate and se-
vere disease had significantly higher viral loads than those 
with mild disease. Immunity following rotavirus vaccination 
mimics that following natural rotavirus exposure, which gen-
erates incremental protection against rotavirus gastroenteritis 
of increasing severity [11]. It is therefore plausible that vac-
cination could reduce the severity of rotavirus gastroenteritis 
episodes and, thereby, decrease the total shedding burden of 
rotavirus in the community. The association between dis-
ease severity and viral load is most striking between mild and 
moderate/severe disease; however, the numbers of children 
recruited into this study with mild disease were small, pre-
sumably because most children with mild disease do not 
present to health-care facilities. The analysis is sensitive to the 
presence of children with mild disease, but robust to different 
analytical approaches. Further studies are required to ensure 
that children with mild disease are appropriately represented 
and to formally evaluate the potential for vaccination to re-
duce the viral shedding density at the population level.
Increasing anti-rotavirus IgA titres at presentation were 
negatively associated with fecal viral load, independent of 
disease severity. Serum anti-rotavirus IgA titres are known 
to correlate with intestinal IgA titres [13], and it is plausible 
that higher levels of intestinal IgA could reduce viral replica-
tion and, thereby, the fecal viral load. However, only a quarter 
of the vaccinated children in our cohort reached the criteria 
for seroconversion, and anti-rotavirus IgA titres are an im-
perfect correlate of protection, particularly in low-income 
settings [14].
We found that rotavirus viral shedding density is negatively 
associated with WHZ, implying that increasingly malnour-
ished children shed more of the virus. Careful interpretation 
is required, as the standard deviations for our anthropometric 
measurements are outside the World Health Organization range 
for data quality assessment purposes [8]. Nevertheless, the neg-
ative association between WHZ and viral load is corroborated 
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Figure 1. A, Rotavirus shedding over time in symptomatic children. The dots rep-
resent the raw data on log (viral load), and the red fitted line represents the regres-
sion line including a quadratic term, to account for the non-linear nature of viral 
decay. Confidence bounds represent the 95% confidence limits on either side of the 
fitted value. Regression coefficients are given in Supplementary Table S3. B, Kaplan 
Meier plot of time to cessation of shedding in index children. The analysis time is 
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arm circumference and viral load (Table 1). It is biologically 
plausible that children with poorer nutritional states could shed 
more rotavirus due to a reduced ability to mount mucosal im-
munity, differences in intestinal microbiome and mucosal in-
tegrity, and a tendency for more severe rotavirus disease in the 
presence of malnutrition [15].
Conclusions
Children in Malawi shed large quantities of rotavirus for an ex-
tended period following an episode of moderate-to-severe di-
arrhea, despite prior vaccination. Persistently high fecal virus 
shedding may contribute to the high prevalence of asympto-
matic infections in young children in the community and to 
ongoing rotavirus transmission. While reduced disease severity 
in Malawian children was associated with lower viral shedding 
density, the potential impact of this on population-level rota-
virus transmission remains to be determined.
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Diseases online. Consisting of data provided by the authors to 
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